The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Elevance Health (NYSE:ELV), Intuitive Surgical (NASDAQ:ISRG), Regeneron Pharmaceuticals (NASDAQ:REGN).
The investment seeks long-term capital appreciation.
The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies.
The average market capitalization across the T. Rowe Price Health Sciences MF is 162.93B. The market cap for tickers in the group ranges from 86.95B to 561.54B. LLY holds the highest valuation in this group at 561.54B. The lowest valued company is REGN at 86.95B.
The average weekly volume growth across all stocks in the T. Rowe Price Health Sciences MF was -63%. For the same stocks of the MF, the average monthly volume growth was -71% and the average quarterly volume growth was -64%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 41
P/E Growth Rating: 42
Price Growth Rating: 46
SMR Rating: 61
Profit Risk Rating: 31
Seasonality Score: 11 (-100 ... +100)